Dr Lal PathLabs Q2FY26 revenue rises 10.7%, approves 1:1 bonus issue

Dr Lal PathLabs reported revenue of ₹731 crore for Q2FY26, up 10.7 percent from ₹660 crore last year, with profit after tax rising to ₹152 crore, a 16.4 percent increase. EBITDA stood at ₹224 crore, marking a 10.8 percent rise year-on-year, and the EBITDA margin was 30.7 percent. The company attributed its performance to increased testing volumes and network expansion, especially in Tier-III and Tier-IV towns. An interim dividend of ₹7 per equity share was declared, along with approval for a 1:1 bonus share issue, granting one bonus share for every share held as of the record date. Dr Lal PathLabs continues to expand its infrastructure, operating 298 clinical laboratories, 6,607 patient service centers, and 12,365 pickup points as of September 2025, serving individuals, hospitals, and corporate clients. The stock traded around ₹3,137 after the announcement.

“At Dr Lal PathLabs, we see this decade as one for deep transformation. The burden of chronic and lifestyle-related diseases continues to rise, demanding greater focus on early detection and continuous monitoring. As new therapies for diabetes, hypertension, and obesity become more widely available, the role of diagnostics will only intensify. Further, as policy initiatives like Ayushman Bharat expand access across Tier-2 and Tier-3 regions, diagnostics are emerging as the essential first step in care delivery. The growing awareness around preventive health, supported by rapid digital adoption, is helping millions of citizens engage with organized healthcare for the first time. This convergence of accessibility, affordability, and accountability marks a defining moment for the sector, and we are privileged to play a prime role in it. As the shift from unorganized to organized healthcare continues, we stand ready to lead the way responsibly and to contribute meaningfully to India’s ambition of universal healthcare,” said (Hony.) Brig. Dr. Arvind Lal, Executive Chairman, Dr. Lal PathLabs.
MB Bureau